TB-222-023

N/A

Report date: 2023/08/10 14:29:28

Base Information

Drug NameTB-222-023
Drug Alias NameTB-222-023TB-222023
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionGlucagon-like peptide 1 receptor antagonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsCongenital Hyperinsulinism
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTwist Bioscience HQ
China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of PhiladelphiaTwist Bioscience HQ
Inactive CompaniesN/A
Active IndicationsCongenital Hyperinsulinism
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A